BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that still lacks reliable diagnostic biomarkers. This study aims to evaluate the diagnostic and prognostic potential of CSF total Tau (t-Tau), phospho-Tau (p-Tau) and p-Tau/t-Tau ratio in ALS patients using CSF neurofilament light (NFL) as the reference biomarker. METHODS: Eighty-five incident ALS, 30 ALS-mimicking (AM) diseases and 51 other non-neurodegenerative diseases (ONND) were included in the study. RESULTS: ALS patients had higher levels of CSF t-Tau and lower p-Tau/t-Tau ratio than AM (p = 0.005 and p = 0.006) and ONND (p < 0.001). CSF t-Tau levels discriminated ALS from AM with a sensitivity of 69% and specificity of 60%, and from ONND with a sensitivity of 88% and specificity of 51%. These values were lower than the accuracy of CSF NFL in ALS (sensitivity 86% and specificity 87% in distinguishing ALS from AM and sensitivity 83% and specificity 75% from ONND); CSF t-Tau correlated with progression rate and SNIP. CSF p-Tau did not show relation with any ALS clinical features. CSF NFL significantly correlated with all considered clinical parameters. High levels of CSF t-Tau and NFL were related to poor survival. CONCLUSION: CSF t-Tau showed no reliable diagnostic significance but the relation between the high levels of CSF t-Tau and short survival suggests the potential prognostic role of this biomarker in ALS. However, CSF NFL was confirmed to be the most reliable and efficient tool for diagnosis and prediction of clinical progression and survival in ALS patients.
BACKGROUND:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that still lacks reliable diagnostic biomarkers. This study aims to evaluate the diagnostic and prognostic potential of CSF total Tau (t-Tau), phospho-Tau (p-Tau) and p-Tau/t-Tau ratio in ALS patients using CSF neurofilament light (NFL) as the reference biomarker. METHODS: Eighty-five incident ALS, 30 ALS-mimicking (AM) diseases and 51 other non-neurodegenerative diseases (ONND) were included in the study. RESULTS: ALS patients had higher levels of CSF t-Tau and lower p-Tau/t-Tau ratio than AM (p = 0.005 and p = 0.006) and ONND (p < 0.001). CSF t-Tau levels discriminated ALS from AM with a sensitivity of 69% and specificity of 60%, and from ONND with a sensitivity of 88% and specificity of 51%. These values were lower than the accuracy of CSF NFL in ALS (sensitivity 86% and specificity 87% in distinguishing ALS from AM and sensitivity 83% and specificity 75% from ONND); CSF t-Tau correlated with progression rate and SNIP. CSF p-Tau did not show relation with any ALS clinical features. CSF NFL significantly correlated with all considered clinical parameters. High levels of CSF t-Tau and NFL were related to poor survival. CONCLUSION: CSF t-Tau showed no reliable diagnostic significance but the relation between the high levels of CSF t-Tau and short survival suggests the potential prognostic role of this biomarker in ALS. However, CSF NFL was confirmed to be the most reliable and efficient tool for diagnosis and prediction of clinical progression and survival in ALS patients.
Entities:
Keywords:
Amyotrophic lateral sclerosis; Biomarkers; CSF; Neurofilament light; Phospho-Tau; Total Tau
Authors: Carlo Wilke; Christian Deuschle; Tim W Rattay; Walter Maetzler; Matthis Synofzik Journal: Neurobiol Aging Date: 2014-10-18 Impact factor: 4.673
Authors: Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: F J Jiménez-Jiménez; A Hernánz; S Medina-Acebrón; F de Bustos; J M Zurdo; H Alonso; I Puertas; B Barcenilla; Y Sayed; F Cabrera-Valdivia Journal: Acta Neurol Scand Date: 2005-02 Impact factor: 3.209
Authors: Murray Grossman; Lauren Elman; Leo McCluskey; Corey T McMillan; Ashley Boller; John Powers; Katya Rascovsky; William Hu; Les Shaw; David J Irwin; Virginia M-Y Lee; John Q Trojanowski Journal: JAMA Neurol Date: 2014-04 Impact factor: 18.302
Authors: Stefan Lehnert; Julia Costa; Mamede de Carvalho; Janine Kirby; Magdalena Kuzma-Kozakiewicz; Claudia Morelli; Wim Robberecht; Pamela Shaw; Vincenzo Silani; Petra Steinacker; Hayrettin Tumani; Philip Van Damme; Albert Ludolph; Markus Otto Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2014-02-28 Impact factor: 4.092
Authors: Débora Lanznaster; Rudolf C Hergesheimer; Salah Eddine Bakkouche; Stephane Beltran; Patrick Vourc'h; Christian R Andres; Diane Dufour-Rainfray; Philippe Corcia; Hélène Blasco Journal: Int J Mol Sci Date: 2020-04-21 Impact factor: 5.923
Authors: Tiziana Petrozziello; Ana C Amaral; Simon Dujardin; Sali M K Farhan; James Chan; Bianca A Trombetta; Pia Kivisäkk; Alexandra N Mills; Evan A Bordt; Spencer E Kim; Patrick M Dooley; Caitlin Commins; Theresa R Connors; Derek H Oakley; Anubrata Ghosal; Teresa Gomez-Isla; Bradley T Hyman; Steven E Arnold; Tara Spires-Jones; Merit E Cudkowicz; James D Berry; Ghazaleh Sadri-Vakili Journal: Brain Pathol Date: 2021-11-14 Impact factor: 6.508
Authors: C Delaby; D Alcolea; M Carmona-Iragui; I Illán-Gala; E Morenas-Rodríguez; I Barroeta; M Altuna; T Estellés; M Santos-Santos; J Turon-Sans; L Muñoz; R Ribosa-Nogué; I Sala-Matavera; B Sánchez-Saudinos; A Subirana; L Videla; B Benejam; S Sirisi; S Lehmann; O Belbin; J Clarimon; R Blesa; J Pagonabarraga; R Rojas-Garcia; J Fortea; A Lleó Journal: Sci Rep Date: 2020-06-08 Impact factor: 4.379
Authors: Andreas Totzeck; Benjamin Stolte; Kathrin Kizina; Saskia Bolz; Melina Schlag; Andreas Thimm; Christoph Kleinschnitz; Tim Hagenacker Journal: Int J Mol Sci Date: 2019-10-30 Impact factor: 5.923